Pharmacometabolomics of Psychotropic Drugs: Treatment Response, Adverse Effects, and Precision Psychiatry—A Narrative Review

1. Introduction

Psychotropic drugs remain the cornerstone of treatment for depression, schizophrenia, and bipolar disorder, yet their use is defined by unpredictable outcomes. On average, 40% of patients do not respond to a given antidepressant — defined as a 50% or greater reduction in symptoms — and over two-thirds do not achieve complete remission after antidepressant therapy [1]. Antipsychotic treatment in schizophrenia is similarly heterogeneous, with up to 30% of patients showing poor response to first-line agents, and metabolic adverse effects such as weight gain, dyslipidemia, and diabetes frequently limit treatment regardless of efficacy [2]. For decades, efforts to personalize prescribing have centered on pharmacogenomics — the study of how genetic variation alters drug metabolism and targets. These efforts, while valuable, have explained only a small proportion of the observed variability in outcomes, in part because drug response is shaped by the dynamic interplay of genetics, environment, diet, concurrent illness, and the gut microbiome — influences that static genomic data cannot capture [3,4].

Metabolomics offers a complementary perspective. Because metabolites are the downstream products of every cellular, genetic, and environmental influence, an individual’s metabolic state at any moment reflects his or her overall physiological and pathological status [5]. The application of metabolomics to pharmacology has given rise to pharmacometabolomics, a discipline defined by the use of metabolic profiles — obtained before, during, or after drug treatment — to predict, explain, and monitor drug response phenotypes, including both efficacy and toxicity [3,6]. The central construct is the “metabotype”: the totality of an individual’s metabolic characteristics, a phenotype in its own right that integrates genetic constitution, disease state, demographic and lifestyle factors, and cumulative drug and environmental exposures [7]. This review synthesizes the evidence that pharmacometabolomics can predict psychotropic treatment response, illuminate the biochemical pathways through which adverse effects arise, and contribute the metabolomic layer to precision psychiatry.

2. Conceptual Foundations of Pharmacometabolomics

2.1. From Metabolomics to Pharmacometabolomics

Metabolomics captures global biochemical events by assaying thousands of small molecules in cells, tissues, organs, or biological fluids and applying informatic techniques to define metabolomic signatures [5]. The discipline’s relevance to pharmacology rests on three propositions: that an individual’s metabolic state represents overall physiologic status; that drugs perturb this state in characteristic, measurable ways; and that baseline variability in metabolic state contributes to variability in drug response [3,5]. Pharmacometabolomics studies therefore fall into two broad types: those that use pre-dose metabolic profiles to predict who will respond and who will suffer toxicity, and those that use post-dose profiles to map a drug’s mechanism of action and the biochemical basis of adverse reactions [6]. Because the metabolome integrates host genetics, the gut microbiome, nutrition, age, sex, stress, and health status, pharmacometabolomics is uniquely positioned to capture the “non-genetic” components of human heterogeneity that pharmacogenomics alone cannot [3,7]. The field’s origins trace to the concept of pharmaco-metabonomics — prediction of drug or xenobiotic intervention outcome based on pre-intervention metabolite signatures — which has since broadened and matured into contemporary pharmacometabolomics [8].

2.2. The Metabotype as an Integrative Phenotype

The metabotype reflects not only the constitution of the individual — genetic makeup, sex, age, ethnicity — but also the impact of disease, environmental exposures such as diet and circadian rhythms, and the effects of past and concomitant treatments [7]. Landmark population-scale work established that human metabolic individuality is a stable, heritable trait with direct consequences for biomedical and pharmaceutical research [9]. Within psychiatry, metabotypes have been shown to inform disease heterogeneity and treatment outcomes, and metabolic profiles have provided novel insights into variation of response to antipsychotics, antidepressants, statins, antihypertensives, and antiplatelet therapies [7]. Because the metabolome is ontologically closer to the drug target than the genome, transcriptome, or proteome, it offers a more direct readout of drug action — and because it is dynamic, it can capture the continuous, bidirectional interactions between treatment and physiology that static “omics” cannot [3,4].

2.3. Analytical Platforms and Experimental Designs

Pharmacometabolomic investigations employ complementary analytical platforms. Nuclear magnetic resonance spectroscopy provides comprehensive, unbiased quantification of a wide range of compounds, while mass spectrometry — including liquid chromatography-MS, tandem MS, GC-MS, and liquid chromatography with electrochemical array detection — provides high sensitivity for targeted and untargeted profiling [8,10]. Untargeted metabolomics measures all detectable analytes, including unknowns, and requires advanced chemometric reduction of the data; targeted metabolomics provides robust, high-throughput quantification of preselected, annotated metabolite classes with internal standards [11]. In psychiatry, serum and plasma are the dominant matrices because they are minimally invasive and analytically tractable, and both approaches have been applied to antidepressant, antipsychotic, and mood-stabilizer research [10,11].

2.4. Pharmacometabolomics-Informed Pharmacogenomics

A defining feature of the field is its explicit union with pharmacogenomics. The paradigmatic example is the glycine story in antidepressant response (Section 3.2), in which a baseline metabolomic signature — elevated glycine predicting poorer SSRI outcome — was used to nominate glycine-metabolizing enzymes as candidate pharmacogenomic loci, leading to the identification of a glycine dehydrogenase single-nucleotide polymorphism associated with response [1,12]. This strategy — using metabolites to inform genetic interrogation — has been formalized as pharmacometabolomics-informed pharmacogenomics, in which metabotypes and genotypes are collected in the same cohorts and interrogated jointly [4,13]. The approach exploits a key insight: genetically influenced metabotypes can act as intermediate phenotypes that bridge DNA variation and clinical drug response, capturing environmental and microbiome-level influences that genes alone miss [4,7].

3. Pharmacometabolomics of Antidepressants: Predicting Treatment Response

3.1. Sertraline and Placebo: Proof-of-Concept Studies

The first systematic proof-of-concept for pharmacometabolomics in psychiatry came from the sertraline programme. In a double-blind, 4-week trial, outpatients with major depressive disorder were randomly assigned to sertraline (n = 35) or placebo (n = 40); response rates were 21/35 (60%) for sertraline and 20/40 (50%) for placebo (χ² = 0.75, p = 0.39), and no valid biomarkers of depression or of response to medication or placebo existed at the time [14,15]. Using a targeted electrochemistry-based LCECA platform to profile serum, the group demonstrated that pretreatment metabolic profiles could discriminate, at baseline, individuals who would respond to sertraline or to placebo from those who would not — establishing the metabotype as a predictor of response independent of drug assignment — and provided a template for placebo-arm-aware study designs in psychopharmacology [13,14].

A companion study mapped the global biochemical changes induced by one and four weeks of sertraline or placebo treatment and correlated these changes with treatment outcome, showing that early biochemical perturbations in the methoxyindole branch of tryptophan metabolism tracked eventual response [13,15]. Specifically, response to sertraline or placebo was accompanied by increases in 5-methoxytryptophol and melatonin, with decreases in the kynurenine:melatonin and 3-hydroxykynurenine:melatonin ratios [16]. These findings established the principle that differential regulation of tryptophan metabolic branches contributes to variation in antidepressant response and that such regulation can be measured in peripheral blood within the first days to weeks of treatment [15].

3.2. Citalopram/Escitalopram: Glycine, Sphingolipids, and Beyond

Complementary work in the citalopram/escitalopram programme identified glycine as a baseline predictor of response. In a targeted metabolomic investigation, several metabolites in the nitrogen metabolism pathway — predominantly glycine — were negatively associated with SSRI treatment outcome, such that elevated glycine signaled decreased response [12]. Pharmacometabolomics-informed pharmacogenomics then identified a commonly occurring SNP (rs10975641) in the glycine dehydrogenase gene associated with SSRI treatment outcomes; genotyping of DNA from 1,926 patients confirmed significant association with response in white non-Hispanics (1,245 individuals) and across the full sample after adjustment for ethnicity [1,12]. The same group reported that baseline and 8-week profiles of serotonin-related and one-carbon metabolism metabolites — including decreases in sarcosine correlated with decreases in serotonin, reductions in histidine and kynurenine inversely associated with improvements in HRSD17 scores, and increases in methionine sulfoxide and its ratio to methionine (P < 0.0008) — inform the mechanism of action of citalopram/escitalopram [17,18].

Metabolomic characterization of exposure and response to citalopram/escitalopram further implicated all three branches of tryptophan metabolism — to serotonin/melatonin/5-hydroxyindoleacetate, to kynurenine, and to indole derivatives — as being affected in the depressed state and modulated by treatment [18]. In an independent replication among 529 depressed patients treated with citalopram/escitalopram for 8 weeks, baseline lipids such as phosphatidylcholines and nonhydroxylated sphingomyelins, together with metabolites of the tryptophan, tyrosine, and purine pathways, were predictive of response [10,19]. The sphingolipid signal was extended in the CO-MED trial, where an increased ratio of hydroxylated to non-hydroxylated sphingomyelins at baseline and its change over treatment predicted better symptom reduction, and where all metabolite-based models outperformed models using only clinical and sociodemographic variables [20]. Taken together, these studies converge on a reproducible, multi-pathway metabotype — glycine/one-carbon metabolism, tryptophan–kynurenine flux, sphingolipids, and acylcarnitines — that carries predictive information for SSRI response across independent cohorts [1,12,17,20].

3.3. The Tryptophan–Kynurenine Pathway as a Shared Biomarker Axis

The tryptophan–kynurenine pathway has emerged as the most consistent single axis in antidepressant pharmacometabolomics, functioning as an overlapping biomarker for diagnosis and treatment response. In 62 patients completing approximately six weeks of escitalopram treatment, kynurenic acid and kynurenine were significantly and negatively associated with HRSD reduction, and kynurenic acid — detected in only one of 73 measured metabolites — was both lower in depression and associated with better therapeutic response when lower [21]. This dual diagnostic–predictive status is clinically attractive because it implies a single biological readout for patient stratification: approximately 40% of MDD patients achieve remission after initial treatment, and biomarkers that reduce exposure to ineffective therapies are precisely what current practice lacks [1,21]. Meta-analytic and review-level syntheses confirm that tryptophan, its kynurenine branch, and the downstream neuroactive metabolites — neuroprotective kynurenic and picolinic acids versus neurotoxic 3-hydroxykynurenine and quinolinic acid — are central to both MDD pathophysiology and antidepressant response, and these conclusions are mirrored in ketamine research (Section 3.5) [10,16,22].

3.4. Clinical Cohorts: CO-MED and CAN-BIND-1

Larger, pragmatic clinical cohorts have begun to consolidate these findings. In the CO-MED trial — which included treatment arms with venlafaxine, bupropion, and mirtazapine in addition to an SSRI — targeted metabolomic modeling identified baseline metabolites predicting depression recovery, with sphingomyelin hydroxylation status emerging as a robust predictor and with metabolomic models exceeding the predictive performance of clinical variables alone [20]. The CAN-BIND-1 consortium, applying comprehensive metabolic phenotyping in depressed patients treated with escitalopram and escitalopram–bupropion, confirmed that baseline plasma lipids and metabolites of the tryptophan, tyrosine, and purine pathways predict response, and that glycine is negatively associated with escitalopram outcome — while simultaneously linking changes in glutamate and circulating phospholipids to response to ketamine and esketamine [19]. These multi-site studies are important because they move pharmacometabolomics from single-center discovery toward validation in heterogeneous, clinically realistic samples [19,20].

3.5. Ketamine and Esketamine: Signatures of Rapid Response

The rapid-acting antidepressant ketamine has provided particularly clean pharmacometabolomic signal because of its fast, measurable time course. In patients with refractory major depressive disorder, significant metabolite changes were detectable in blood within 2 hours of a single ketamine or esketamine infusion and correlated with the antidepressant response observed approximately 2 days later; the most notable changes implicated glutamic acid (increased at 2 hours post-exposure), the urea cycle (citrulline, arginine, ornithine), and tryptophan metabolism (indole-3-acetate, methionine) [23]. In a placebo-controlled crossover study, circulating kynurenine and the kynurenine:tryptophan ratio were lower among responders at 230 minutes and the difference in the ratio persisted to day 1 (p = 0.035), while among kynurenine metabolites only anthranilic acid was significantly higher in responders at 230 minutes (p = 0.004) [22]. Metabolite–outcome relationships extend to drug enantiomers and side effects: higher levels of the norketamine enantiomer (2S,5S;2R,5R)-norketamine were associated with nonresponse in bipolar depression within 230 minutes, and increased levels of several hydroxylated ketamine metabolites were associated with fewer psychotomimetic side effects [24]. Notably, no association was found between several cytochrome P450 genes and ketamine antidepressant efficacy, illustrating precisely the class of variance — beyond CYP genotype — that pharmacometabolomics is designed to capture [24]. These studies together link a systemic metabolic response (glutamatergic, urea-cycle, and kynurenine flux) to the drug’s glutamatergic mechanism and to its acute and persistent efficacy [22,23,24].

4. Pharmacometabolomics of Antipsychotics

4.1. Metabolic Signatures of Schizophrenia and Antipsychotic Action

Metabolomic profiling in schizophrenia has pursued two goals: identifying disease biomarkers and tracking treatment effects. In a seminal GC-MS study of unmedicated schizophrenia patients before and after 8 weeks of risperidone monotherapy, 22 marker metabolites completely separated patients from matched healthy controls, with citrate, palmitic acid, myo-inositol, and allantoin showing the best combined classification performance; 20 marker metabolites then separated post-treatment from pre-treatment samples, with myo-inositol, uric acid, and tryptophan showing maximum combined classification performance [25]. Pathways disturbed in the patients — energy metabolism, antioxidant defense, neurotransmitter metabolism, fatty acid biosynthesis, and phospholipid metabolism — were partially normalized by risperidone therapy, indicating that the drug’s metabolic effects are at least in part restorative [25]. Complementing this, capillary electrophoresis-time-of-flight mass spectrometry of first-episode schizophrenia patients (n = 30, with four drug-naïve samples) versus healthy controls (n = 38) and autism spectrum disorder participants (n = 15) identified five robustly altered metabolites — increased creatine and decreased betaine, nonanoic acid, benzoic acid, and perillic acid — suggesting onset-associated metabolic alterations consistent across independent sample sets [26].

4.2. Lipidomics of Antipsychotic Response

Lipidomic studies have connected antipsychotic exposure to measurable changes in membrane and circulating lipids. Schizophrenia itself is associated with major defects in polyunsaturated fatty acid composition within phosphatidylethanolamine and phosphatidylcholine lipid classes, pointing to systemic membrane pathology rather than a pure drug effect [27]. In a 26-week randomized trial of 317 patients, aripiprazole was associated with less weight gain and smaller increases in total cholesterol and triacylglycerols than olanzapine — the kind of differential drug signature amenable to lipidomic monitoring [27]. Blood-based lipidomics has also been applied to discriminate response phenotypes in patients treated with olanzapine, risperidone, and quetiapine, motivated in part by the observation that approximately 40% of patients respond inadequately and around 60% abandon treatment because of intolerable side effects [2]. These lipid signatures — combined with the acute lipid effects described below — position the lipidome as a tractable readout of antipsychotic pharmacodynamics and pharmacotoxicity [2,27].

4.3. The Metabolome of Antipsychotic-Induced Metabolic Adversity

The adverse metabolic phenotype of antipsychotics has emerged as one of the clearest targets for pharmacometabolomics, because drug exposure, microbial shifts, and metabolic outcomes can be traced through the same small-molecule network. Acute studies demonstrate direct, weight-independent drug effects on lipid metabolism: a single dose of clozapine in rats elevated serum free fatty acids as early as 15 minutes after injection, peaking at 322±50% (P < 0.001) at 30 minutes, while olanzapine produced a peak rise of 205±74% (P < 0.01) within 1 hour — rapid lipolytic signals that precede any change in body weight [28]. These acute metabolic perturbations are relevant to the diabetes burden among antipsychotic users, which is four-fold higher than in matched controls [29].

In a mouse model of antipsychotic-induced hyperphagia and weight gain, pharmacometabolomic profiling identified one hypothalamic metabolite (indoxylsulfuric acid) and 389 plasma metabolites (including 19 known) specifically associated with the phenotype: citrulline, tricosenoic acid, docosadienoic acid, and palmitoleic acid increased, while serine, asparagine, and arachidonic acid and its derivatives decreased; all changes were blocked by co-treatment with minocycline, demonstrating that the metabolite signature tracks the pharmacologic reversibility of the phenotype [29]. In first-episode psychosis patients, prospective studies have shown that weight gain over the first year of antipsychotic treatment is associated with baseline elevations of triacylglycerols with low carbon number and double-bond count — lipids linked to increased liver fat and insulin resistance — independent of obesity, indicating that metabolite profiles measured pre-treatment or early in treatment can identify patients most vulnerable to metabolic comorbidity [30]. Systematic metabolomic reviews of the antipsychotic–metabolic syndrome interface emphasize both untargeted discovery of altered pathways in schizophrenia brain tissue and the centrality of energy-balance-regulating brain regions targeted by these drugs, arguing that the metabolome provides a mechanistic bridge between central drug action and peripheral metabolic dysfunction [11].

5. Mood Stabilizers and Bipolar Disorder

Metabolomic investigation of mood stabilizers, although younger than the antidepressant literature, has yielded distinctive signatures. Early 1H NMR-based metabolic profiling of serum distinguished patients with bipolar disorder (n = 25) from controls (n = 25) and separated lithium-treated (n = 15) from other-medication-treated (n = 10) patients, with 24 identified metabolites — chiefly lipids and lipid-metabolism-related molecules (acetate, choline, myo-inositol) and key amino acids (glutamate, glutamine) — contributing to the discrimination; the profiles suggested that some changes reflect lithium- and other-medication-provoked metabolic effects while others relate to the disorder itself [31]. Newer work using dried blood spots from the UK Delta study has demonstrated that a reproducible metabolomic signature can differentiate bipolar from unipolar depression during depressive episodes, addressing the clinically critical problem of misdiagnosis and pointing toward metabolomic support for treatment selection in mood disorders [32]. For lithium specifically, integrative-science reviews argue that no single biomarker will adequately capture response or tolerability and advocate biosignatures combining clinical phenotyping with multimodal biomarkers — blood omics, neuroimaging, actigraphy — to define a valid lithium-response phenotype and enable composite prediction algorithms [33]. This convergence of metabolomics with clinical and digital phenotyping exemplifies the multi-omic design recommended for the field as a whole [33,34].

6. The Microbiome in the Pharmacometabolome: Xenobiotic Metabolism and Adverse Drug Reactions

An increasingly important dimension of the pharmacometabolome is its microbial component. Xenobiotic metabolomics — the application of metabolomics to the fate of foreign compounds — has demonstrated that drug administration produces broad, reproducible changes across the metabolome that encode both exposure and biological effect [12]. The gut microbiota contributes substantially to this space: the drug–microbe relationship is bidirectional, with the microbiota metabolizing psychotropics into products with altered activity, toxicity, and lifetime within the body [35]. Approximately two-thirds of 271 tested oral drugs are metabolized by at least one of 76 cultured human gut bacterial strains [36], and more than 40 drug substrates have been identified for gastrointestinal microbes, which perform reductions, hydrolyses, deconjugations, ring cleavages, and demethylations largely distinct from hepatic biotransformation chemistry [37]. Because microbial enzyme repertoires vary considerably between individuals, the extent and products of microbial drug metabolism are a plausible source of the wide interindividual variability in both psychotropic efficacy and adverse reactions [38]. The microbiome also modulates host xenobiotic-metabolizing enzymes, including CYP450s and multidrug-resistance transporters, and supports mucosal integrity that limits drug absorption [39]. Microbial β-glucuronidases can cleave glucuronic acid moieties added during hepatic phase II metabolism, increasing reabsorption of the parent compound and thereby raising systemic exposure and the risk of toxicity [40]. Finally, high-throughput screening demonstrates that 24% of drugs with human targets — with antipsychotics overrepresented — directly inhibit gut bacterial growth, meaning that psychotropics simultaneously remodel the very microbial community that metabolizes them and generates toxic or inactive products [41]. These interconnected loops argue that microbial metabolites and drug–microbiome–host metabolic interactions must be incorporated into pharmacometabolomic models of psychotropic response and adverse-effect prediction [35,36,38].

7. Toward Precision Psychiatry: Integration and Translation

7.1. From Pharmacometabolomics to Quantitative Systems Pharmacology

The scaling of clinical pharmacological data and the merger of systems biology with pharmacology has produced the emerging discipline of quantitative and systems pharmacology, in which large datasets capturing the effects of the genome, gut microbiome, and environmental exposures are modeled at the network level [4]. Within this framework, pharmacometabolomics informs and complements pharmacogenomics, together providing the building blocks for QSP and for precision medicine initiatives [4,7]. Technically, pharmacometabolomics can prospectively inform both pharmacokinetic and pharmacodynamic processes — guiding drug selection and dosing — and reviews of the field argue that metabolite-based biomarkers of exposure and effect should be integrated into pharmacokinetic–pharmacodynamic modeling from early-phase development onward [42]. The distinguishing strength of the metabolomic contribution is its capacity to capture the dynamics of the whole organism — including diet, microbiota, circadian influences, and polypharmacy — in ways that static genomic and transcriptomic measures cannot [3,7].

7.2. Clinical Trials, Regulatory Pathways, and Implementation Challenges

The translational pipeline for pharmacometabolomic biomarkers is still being built. Analysis of the clinicaltrials.gov registry over the 18 years to 2015 identified 469 studies using metabolomic biomarkers, of which 166 (35.4%) were drug-development studies and only 7 (1.5%) involved development of new molecular entities; overall, metabolomics was used in fewer than 0.5% of reported clinical trials, with 93.4% of studies conducted by academic institutions [8]. Although utilization grew after 2006, adoption in drug development remains minimal, constrained by the analytical, bioinformatic, and interpretive infrastructure required [8]. Regulatory pathways, however, are now explicit: biomarker qualification in clinical trials is described in US law under the 21st Century Cures Act, and guidance exists on defining the context of use for metabolomic biomarkers submitted to the FDA [6]. Reviews of the field recommend that metabolomic biomarkers be validated within the same developmental framework as diagnostic biomarkers — discovery, analytical validation, clinical qualification — and that biobanking, standardized platforms, and data-sharing infrastructure be established early [6,8].

7.3. Priorities for the Field

Several priorities follow from the evidence reviewed. First, prospective, drug-naïve cohorts with serial metabolomic sampling are needed to define the timing and dose-dependence of metabotype changes and to distinguish illness-related from drug-related metabolic signatures [19,20]. Second, pharmacometabolomics-informed pharmacogenomics should be applied systematically across antidepressant, antipsychotic, and mood-stabilizer programmes, since the glycine–GLDC paradigm demonstrates the power of using metabolites to nominate genes [1,12]. Third, gut-microbial metabolism and microbial metabolites must be integrated into pharmacometabolomic models, given the documented bacterial transformation of psychotropics and its variability across individuals [35,36,38,40]. Fourth, lipidomic monitoring should be incorporated into trials of antipsychotics with divergent metabolic liabilities to enable early identification of patients at risk of weight gain and dyslipidemia [27,28,29]. Finally, standardized reporting, external validation, and regulatory engagement are required to move promising metabotypes into clinical decision support [6,8].

8. Conclusions

Pharmacometabolomics has matured from a methodological aspiration into a demonstrably useful science of drug response. Pretreatment metabotypes predict response to sertraline, escitalopram, and ketamine; the tryptophan–kynurenine axis provides overlapping diagnostic and predictive biomarkers in depression; glycine and sphingolipid signatures nominate pharmacogenomic targets and stratify SSRI outcomes; and lipidomic and metabolomic profiles track antipsychotic-induced lipolysis, weight gain, and diabetes risk, while mood-stabilizer research points toward metabolomic signatures of lithium treatment and bipolar–unipolar differentiation. Because the metabolome integrates genome, environment, microbiome, and disease state, pharmacometabolomics complements pharmacogenomics in ways that static biomarkers cannot, and its formal integration into quantitative systems pharmacology, clinical trial design, and regulatory biomarker qualification is already underway. With prospective validation, standardized platforms, and multi-omics integration, the metabolomic layer of precision psychiatry is poised to convert trial-and-error psychopharmacology into mechanism-informed, individualized prescribing.